MEDICAL DISCLAIMER: This information is for educational purposes only and is not intended as medical advice. It should not be used to diagnose or treat a health problem or disease. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition. This content is modeled after clinical reference tools and provides evidence-based information, but clinical judgment, patient-specific factors, and the most current guidelines should always supersede general recommendations.

---

Sudden Sensorineural Hearing Loss (SSNHL)

Overview

• Definition: Sudden Sensorineural Hearing Loss (SSNHL) is defined as an acute, unexplained unilateral or, rarely, bilateral sensorineural hearing loss of at least 30 decibels (dB) over at least three contiguous audiometric frequencies, occurring within a 72-hour period. It is considered an otologic emergency requiring prompt evaluation.
• Epidemiology:
  • Incidence: Estimated at 5-27 cases per 100,000 people annually, though it is likely underestimated due to spontaneous recovery or lack of presentation.
  • Prevalence: More common in middle-aged adults, with the highest incidence between 40 and 60 years of age.
  • Demographics: Affects men and women equally. Unilateral in about 98% of cases. Bilateral SSNHL is rare (1-2% of cases) and often suggests a systemic cause requiring more extensive workup.
• Classification:
  • Idiopathic SSNHL (ISSNHL): Accounts for approximately 85-90% of cases, where no clear underlying cause can be identified despite thorough investigation. This is the focus of most management guidelines.
  • Secondary SSNHL: Occurs due to an identifiable cause, such as:
    • Infectious: Viral (herpes simplex, varicella-zoster, mumps, measles, HIV), bacterial (syphilis, Lyme disease).
    • Vascular: Vasculitis, hypercoagulable states, vasospasm, emboli, hemorrhage.
    • Autoimmune: Cogan's syndrome, lupus, polyarteritis nodosa, granulomatosis with polyangiitis (Wegener's), relapsing polychondritis.
    • Neurologic: Multiple sclerosis, stroke, vestibular schwannoma (acoustic neuroma), other central nervous system lesions.
    • Traumatic: Head trauma, barotrauma, perilymphatic fistula.
    • Metabolic: Diabetes, thyroid dysfunction.
    • Ototoxic drugs: Aminoglycosides, loop diuretics, cisplatin, NSAIDs (rarely).
    • Meniere's disease: Although typically fluctuating, acute severe drops can mimic SSNHL.
  • Degree of Loss: Can range from mild to profound.

Pathophysiology

• Mechanism: The exact mechanism of idiopathic SSNHL is unknown, but several theories exist:
  • Viral infection: Most widely accepted theory, suggesting a latent viral infection (e.g., herpesviruses) reactivating and causing inflammation or damage to the cochlea or auditory nerve. Evidence includes serologic findings and the effectiveness of corticosteroids.
  • Vascular compromise: Ischemia or thrombosis affecting the cochlear blood supply (e.g., labyrinthine artery). This is supported by the association with cardiovascular risk factors and potential benefit from therapies targeting blood flow.
  • Membrane rupture: Rupture of the Reissner's membrane or oval/round window leading to perilymphatic fistula and mixing of fluids, causing acute sensorineural loss.
  • Autoimmune inner ear disease: An aberrant immune response directed against inner ear structures.
  • Other: Rarely, metabolic disturbances, demyelinating disease, or benign tumors (e.g., vestibular schwannoma) can cause the symptoms.
• Risk Factors:
  • Systemic conditions: Diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease, autoimmune disorders (e.g., lupus, rheumatoid arthritis).
  • Infections: Recent viral illness (e.g., upper respiratory infection).
  • Lifestyle: Smoking, high stress levels (less clear evidence).
  • Age: Middle-aged to older adults.
  • Drug exposure: Ototoxic medications (less common for acute, sudden onset unless very high dose/rapid administration).
• Protective Factors: No specific protective factors for idiopathic SSNHL are well-established. General health promotion, management of chronic diseases (e.g., diabetes, hypertension), and avoidance of ototoxic exposures may theoretically reduce risk for secondary SSNHL.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Sudden hearing loss: The defining symptom, occurring over minutes to hours, or noticed upon awakening. Often unilateral.
  • Tinnitus: Ringing, buzzing, or hissing sound in the affected ear, present in about 70% of cases.
  • Aural fullness: Sensation of pressure or blockage in the ear, common.
• Early Signs: The sudden nature of the hearing loss itself is the earliest and most critical sign. Patients may describe it as if "something just clicked off" or "my ear feels plugged."
• Advanced Signs: If left untreated, the hearing loss may become permanent, leading to significant communication difficulties. Persistent tinnitus can also be debilitating.
• Atypical Presentations:
  • Vertigo/Dizziness: Occurs in 30-50% of patients, suggesting labyrinthine involvement and often associated with a poorer prognosis.
  • Otalgia or Otorrhea: Usually absent in idiopathic SSNHL; their presence suggests infection (e.g., otitis media or externa) or other inflammatory processes.
  • Focal neurological deficits: Suggest a central nervous system (CNS) lesion (e.g., stroke, tumor) requiring urgent neurological evaluation.
  • Bilateral SSNHL: Rare (1-2%), highly suggestive of a systemic cause (e.g., autoimmune, infection, vascular).

Physical Examination

• Inspection:
  • Otoscopy: Typically normal tympanic membrane and ear canal. Look for cerumen impaction, otitis media, tympanic membrane perforation, or signs of trauma, which would suggest a conductive or mixed loss rather than a primary sensorineural loss.
• Palpation:
  • Mastoid/preauricular areas: Usually normal. Tenderness or swelling would point away from isolated SSNHL.
• Special Tests:
  • Tuning Fork Tests (Weber and Rinne): While not a substitute for audiometry, they can quickly indicate the type of hearing loss.
    • Weber test: Performed by placing a vibrating 512 Hz tuning fork on the center of the forehead. In unilateral SSNHL, the sound will lateralize to the unaffected (better-hearing) ear.
    • Rinne test: Performed by comparing air conduction (AC) to bone conduction (BC) behind the ear. In unilateral SSNHL, AC > BC in both ears, but the sound heard by AC will be significantly diminished in the affected ear, consistent with sensorineural loss. If AC < BC in the affected ear, it indicates a conductive hearing loss.
  • Cranial Nerve Examination: Essential to rule out neurological involvement. Pay particular attention to facial nerve function (CN VII) due to its proximity to the auditory nerve (CN VIII) in the internal auditory canal.
  • Balance/Vestibular Exam: Assess for nystagmus, Romberg test, tandem gait, and Dix-Hallpike maneuver if vertigo is a prominent symptom.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and Progression: When did the hearing loss begin? Was it sudden (within 72 hours)? Was it instantaneous or progressive over hours?
  • Unilateral vs. Bilateral: Which ear is affected? Both?
  • Associated Symptoms: Tinnitus (description, severity), aural fullness, vertigo/dizziness, ear pain, discharge, headache, fever, numbness, weakness, facial droop.
  • Precipitating Events: Head trauma, barotrauma (diving, flying), loud noise exposure.
  • Recent Illnesses: Upper respiratory infection, cold sores, viral symptoms.
  • Medical History: Diabetes, hypertension, autoimmune disease, kidney disease, thyroid dysfunction, Meniere's disease, prior ear surgery.
  • Medications: Especially ototoxic drugs (e.g., aminoglycosides, cisplatin, loop diuretics).
  • Neurological Symptoms: Any changes in vision, speech, swallowing, balance, or sensation.
• Red Flags:
  • Bilateral SSNHL: Requires urgent and extensive workup for systemic causes.
  • Focal neurological deficits: Suggests central pathology (e.g., stroke, tumor) or significant retrocochlear lesion.
  • Severe vertigo or disequilibrium: Can indicate significant labyrinthine damage or central lesion.
  • Headache, fever, meningismus: Suggests infection (e.g., meningitis) or inflammatory process.
  • Head trauma: Suggests perilymphatic fistula or temporal bone fracture.

Laboratory Tests

• First-Line: No routine labs are typically indicated for idiopathic SSNHL if the history and physical are unremarkable. Labs are generally reserved for suspected secondary causes:
  • CBC with differential: To assess for infection or hematological disorders.
  • ESR, CRP: Markers of inflammation, useful if autoimmune etiology is suspected.
  • Glucose/HbA1c: To screen for diabetes.
  • Syphilis serology (VDRL/RPR, FTA-ABS): Mandatory in many algorithms given treatability and potential for bilateral or fluctuating loss.
  • Lyme serology: If endemic area or exposure history.
  • Thyroid function tests (TSH, free T4): To rule out thyroid dysfunction.
• Confirmatory: No specific lab test confirms idiopathic SSNHL. Labs confirm underlying secondary causes.
• Monitoring: Lab tests are not used to monitor SSNHL directly but may be used to monitor treatment or progression of underlying systemic diseases.

Imaging

• Recommended:
  • MRI of the internal auditory canal (IAC) with gadolinium contrast:
    • Purpose: The gold standard imaging to rule out retrocochlear pathology, particularly a vestibular schwannoma (acoustic neuroma) or other cerebellopontine angle tumors, which can present as SSNHL in 5-15% of cases. It also visualizes signs of demyelinating disease (e.g., multiple sclerosis) or stroke.
    • Timing: Should be performed in all patients with SSNHL, preferably within weeks of onset (though some experts recommend within 1-2 months).
    • Rationale: The imaging is crucial because the presence of a tumor would significantly alter management.
• Advanced:
  • CT scan of the temporal bone: Not routinely recommended for SSNHL, as it does not adequately visualize soft tissue or small tumors of the IAC. It is useful for evaluating temporal bone fractures, bony labyrinthine anomalies, or otosclerosis, primarily when conductive hearing loss is suspected.
  • MRA/MRV: If a vascular cause (e.g., stroke, venous thrombosis) is suspected, but MRI of the brain/IAC usually suffices for initial workup.

Management

Acute Management

The prognosis of SSNHL is highly time-sensitive, making immediate evaluation and initiation of treatment crucial. - Immediate (within 24-48 hours): - Audiometry: Perform a pure-tone audiogram with speech reception threshold (SRT) and word recognition scores (WRS) to confirm the diagnosis (≥30 dB SNHL over ≥3 contiguous frequencies) and quantify the loss. This is the cornerstone of diagnosis. - Urgent Referral: Refer to an Otolaryngologist (ENT) immediately for confirmation and management planning. - Stabilization: - Corticosteroid therapy: Systemic corticosteroids are the primary treatment for idiopathic SSNHL, ideally initiated within 2 weeks of symptom onset, but still considered up to 4-6 weeks. The mechanism is believed to be anti-inflammatory effects, reducing cochlear edema and ischemia. - Oral Prednisone: - Dose: Varies by guideline, but typically 1 mg/kg/day (maximum 60 mg/day) for 10-14 days, followed by a taper over an additional 5-7 days. Some regimens use a fixed dose (e.g., 60 mg daily for 5-7 days) followed by an abrupt stop or shorter taper. - Rationale: Reduces inflammation and edema in the cochlea. - Contraindications: Uncontrolled diabetes, peptic ulcer disease, glaucoma, severe hypertension, active infection (e.g., tuberculosis), psychosis. - Emergency: While SSNHL is not life-threatening, it is an otologic emergency. Rapid diagnosis and initiation of corticosteroids are paramount to maximizing recovery potential. Patients presenting with bilateral SSNHL or associated neurological deficits require immediate, comprehensive workup including neurology consultation.

Chronic Management

• Pharmacological:
  • Oral Corticosteroids: As above, remain the first-line acute treatment.
  • Intratympanic (IT) Corticosteroids:
    • Agents: Dexamethasone (typically 12-24 mg/mL) or Methylprednisolone (typically 30-40 mg/mL).
    • Delivery: Injected directly into the middle ear space, where it diffuses across the round window membrane into the inner ear.
    • Indications:
      1. Primary therapy: When systemic corticosteroids are contraindicated (e.g., uncontrolled diabetes).
      2. Rescue therapy: If insufficient recovery after initial oral corticosteroid course, or when presentation is delayed (>2 weeks).
      3. Combination therapy: Can be used concurrently with oral steroids, though evidence for superior outcomes over oral monotherapy is mixed.
    • Frequency: Typically 3-4 injections over 1-2 weeks.
    • Advantages: Higher inner ear concentration, fewer systemic side effects.
  • Other Agents (Evidence Lacking/Controversial):
    • Antivirals (e.g., acyclovir): Not routinely recommended as monotherapy or adjunct, given inconsistent evidence for viral etiology in idiopathic cases.
    • Vasodilators/Rheologic agents (e.g., pentoxifylline, hyperbaric oxygen): Hyperbaric oxygen therapy (HBOT) is controversial; some guidelines suggest it as an adjunctive treatment, particularly for profound loss or delayed presentation, but robust evidence is limited. Vasodilators are generally not recommended.
• Non-pharmacological:
  • Hearing Aids: If significant permanent hearing loss persists after treatment and observation (typically after 3-6 months), hearing aids (CROS, BiCROS, or conventional) can improve communication.
  • Cochlear Implants: For profound bilateral SSNHL where hearing aids provide insufficient benefit.
  • Counseling: For hearing loss, tinnitus, and vertigo; provide support and resources (e.g., tinnitus management strategies, vestibular rehabilitation for persistent balance issues).
• Monitoring:
  • Repeat Audiometry: Follow-up audiogram typically 2-4 weeks after treatment completion to assess recovery. Further audiograms may be needed at 3 and 6 months to confirm stability and assess long-term outcome.
  • Long-term follow-up: Monitor for stability of hearing, development of fluctuating hearing loss (suggesting Meniere's), or new neurological symptoms.

Treatment Algorithms

• First-Line:
  1. Confirm Diagnosis: Pure-tone audiometry within 24-48 hours of presentation.
  2. Rule out retrocochlear pathology: MRI of the IAC with gadolinium.
  3. Systemic Corticosteroids: Start oral prednisone (e.g., 1 mg/kg/day, max 60 mg/day, for 10-14 days with taper) within 2 weeks of onset, if no contraindications.
• Second-Line (or primary alternative):
  • Intratympanic Corticosteroids:
    • If oral steroids are contraindicated.
    • As rescue therapy if no significant improvement with oral steroids after 2-4 weeks.
    • As primary therapy, particularly for patients with severe-to-profound loss or when presentation is delayed.
• Refractory Cases:
  • Combined oral and intratympanic corticosteroids: Some clinicians use this upfront for profound loss, though evidence for superiority over monotherapy is mixed.
  • Hyperbaric Oxygen Therapy (HBOT): May be considered as an adjunctive treatment, especially for profound loss or delayed presentation (>2 weeks). Requires specialized facilities and patient suitability. Evidence is not universally conclusive.
  • Rehabilitation: For persistent hearing loss, consider hearing aids, assistive listening devices, or cochlear implantation (for profound loss).
  • Tinnitus management: Cognitive behavioral therapy, sound therapy, neuromodulation techniques.

Complications

• Common:
  • Permanent hearing loss: Despite treatment, a significant number of patients (around 30-40%) will not fully recover hearing, leading to variable degrees of permanent SNHL.
  • Persistent tinnitus: Can be debilitating and impact quality of life.
  • Aural fullness: May persist even if hearing recovers.
  • Balance issues: Chronic dizziness or unsteadiness if vestibular structures were damaged.
• Serious:
  • Missed retrocochlear pathology: Failure to diagnose a vestibular schwannoma or other tumor which could grow and cause more severe neurological deficits or even be life-threatening.
  • Psychological impact: Anxiety, depression, and social isolation due to communication difficulties.
• Long-term:
  • Communication difficulties: Leading to reduced social interaction and potentially affecting employment.
  • Increased risk of falls: If chronic balance issues are present, especially in the elderly.

Prognosis

• Factors:
  • Severity of initial hearing loss: Milder loss (e.g., <40 dB) has a better prognosis than severe or profound loss (>80 dB).
  • Presence of vertigo: Associated with a poorer prognosis for hearing recovery.
  • Age: Younger patients (<40-50 years) tend to have better recovery rates than older patients.
  • Time to treatment: Earlier initiation of corticosteroids (within 2 weeks of onset) significantly improves recovery rates. Delay beyond 4-6 weeks substantially reduces the chance of improvement.
  • Audiometric configuration: Up-sloping audiograms tend to have a better prognosis than down-sloping or flat configurations.
  • Unilateral vs. Bilateral: Unilateral cases generally have better prognosis than bilateral.
• Survival: SSNHL is not a life-threatening condition itself.
• Quality of Life: Can be significantly impacted by permanent hearing loss, especially if severe, affecting communication, social interaction, and mental well-being. Tinnitus can also severely degrade quality of life. Approximately one-third to two-thirds of patients experience some degree of hearing recovery, with complete recovery in about 30% of cases.

Prevention

• Primary: For idiopathic SSNHL, there are no specific primary prevention strategies known. For secondary causes, general health maintenance, managing chronic diseases (e.g., diabetes, hypertension), and avoiding ototoxic exposures may reduce risk.
• Secondary:
  • Early Detection: Educating patients and clinicians about the urgency of sudden hearing loss and the need for prompt evaluation and audiometry is key. "Time is hearing."
  • Prompt Intervention: Rapid initiation of corticosteroid therapy (within 2 weeks) is crucial to maximize the chance of hearing recovery.
• Tertiary:
  • Hearing Rehabilitation: For those with persistent hearing loss, providing appropriate amplification (hearing aids) or cochlear implants can prevent communication disability.
  • Tinnitus Management: Counseling, sound generators, and cognitive behavioral therapy to reduce the impact of chronic tinnitus.
  • Balance Rehabilitation: Vestibular physical therapy for chronic dizziness.

Special Populations

• Pediatric:
  • Rarity: Very rare in children, but often has an identifiable cause (e.g., congenital CMV infection, genetic syndromes, autoimmune disease).
  • Diagnosis: Challenging due to difficulty in obtaining reliable subjective audiometry. Objective tests (ABR, OAE) may be needed.
  • Workup: More extensive workup for etiology is usually warranted.
  • Treatment: Corticosteroid use requires careful risk-benefit analysis.
• Geriatric:
  • Incidence: More common in older adults, who often have more comorbidities (e.g., diabetes, hypertension, cardiovascular disease).
  • Recovery: May have poorer recovery rates compared to younger patients, possibly due to underlying microvascular disease or reduced regenerative capacity.
  • Comorbidities: Steroid use needs careful monitoring for effects on blood glucose, blood pressure, bone density, and glaucoma. Intratympanic steroids may be preferred to reduce systemic exposure.
• Pregnancy:
  • Diagnosis: Same principles apply.
  • Treatment: Corticosteroid use in pregnancy should be weighed carefully. Oral steroids (e.g., prednisone) are generally considered low risk in the second and third trimesters, but benefit should outweigh potential risks, especially in the first trimester. Intratympanic corticosteroids are often preferred to minimize systemic exposure, especially for profound loss.
• Comorbidities:
  • Diabetes Mellitus: Patients with diabetes may have poorer recovery rates with oral steroids due to potential microvascular disease and impaired wound healing. Blood glucose levels must be tightly monitored if systemic corticosteroids are used. Intratympanic steroids might be considered as a primary option to avoid systemic glycemic effects.
  • Autoimmune Diseases: If an underlying autoimmune disease is identified, specific immunosuppressive therapy may be required in addition to corticosteroids.

Clinical Pearls

• Diagnostic:
  • "Time is Hearing": Emphasize the urgency to patients and refer for audiometry and ENT evaluation immediately.
  • "Think Tumor Until Proven Otherwise": Unilateral sensorineural hearing loss, even if sudden, mandates an MRI of the IAC with gadolinium to rule out retrocochlear pathology (especially vestibular schwannoma), even if initial recovery occurs.
  • Audiometry is paramount: The diagnosis of SSNHL cannot be made without a formal pure-tone audiogram. Tuning fork tests are screening tools only.
• Treatment:
  • Steroids are the mainstay: Oral corticosteroids are the primary first-line treatment for idiopathic SSNHL. Intratympanic steroids are valuable for those who fail oral therapy, have contraindications to oral steroids, or present late.
  • Counseling: Educate patients on the time-sensitive nature of treatment, potential for incomplete recovery, and the importance of follow-up.
• Pitfalls:
  • Delay in Diagnosis/Treatment: Misattributing sudden hearing loss to cerumen impaction or eustachian tube dysfunction without performing audiometry can lead to irreversible hearing loss.
  • Failure to perform MRI: Missing a treatable retrocochlear tumor.
  • Over-reliance on tuning fork tests: They are screening tools, not diagnostic for SSNHL.
  • Inadequate steroid dosing/duration: Ensure guideline-consistent dosing and appropriate taper.

Recent Updates

• Guidelines: The American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) updated its clinical practice guideline for Sudden Hearing Loss in 2019. Key updates included stronger recommendations for oral and intratympanic steroids, an emphasis on routine MRI, and a shift away from routine use of antivirals or vasodilators.
• Evidence:
  • Ongoing research explores optimal steroid regimens (oral vs. intratympanic vs. combination), the role of hyperbaric oxygen therapy, and potential novel therapeutic agents.
  • Meta-analyses continue to support the efficacy of corticosteroids, particularly when initiated early.
  • Studies on genetic predispositions and specific viral etiologies are ongoing but have not yet yielded clinically actionable widespread tests or treatments for the idiopathic form.
• Controversies:
  • Role of Hyperbaric Oxygen Therapy (HBOT): While some guidelines suggest it as an option, particularly for profound loss or delayed presentation, the evidence of its efficacy as a standalone or adjunctive treatment remains controversial among experts, with some studies showing benefit and others not.
  • Optimal Steroid Regimen: Debate continues regarding the superiority of oral vs. intratympanic corticosteroids, or whether combination therapy provides a synergistic benefit. The choice often depends on individual patient factors, severity of loss, and provider preference.
  • Management of Refractory Cases: No universally accepted treatment protocol for patients who do not respond to initial steroid therapy, leading to varied approaches.

Key References

• Guidelines:
  • Chandrasekhar SS, et al. Clinical Practice Guideline: Sudden Hearing Loss (Update). Otolaryngology–Head and Neck Surgery. 2019;161(1_suppl):S1-S45. (This is the primary authoritative guideline for SSNHL management in the US).
• Studies:
  • Numerous randomized controlled trials and systematic reviews on the efficacy of oral and intratympanic corticosteroids. Examples include studies by Wilson et al. (1980s) for oral steroids and various more recent trials for intratympanic applications.
• Reviews:
  • Comprehensive reviews published in journals like Laryngoscope, Otolaryngology–Head and Neck Surgery, and Audiology and Neuro-otology.
  • UpToDate and similar evidence-based clinical reference tools (e.g., DynaMed) provide regularly updated summaries.